Abstract
The phenomenon of’ second set’ or ‘accelerated’ rejection which characterizes the rapid destruction of a second tissue or organ transplant from the same donor into the same recipient was first described by Medawar and coworkers. Those observations made in untreated recipients were considered as a major evidence for the immunological mechanisms of allograft rejection since such capacity to reject transplants of donor strain origin in an accelerated mode could be transferred to naive recipients by T cells from the presensitized hosts. Cross-reactive grafts from donors sharing MHC class I and/or class II alleles with the sensitizing donor were also rejected in an accelerated fashion, suggesting that accelerated rejection was mediated by sensitized CD4 + and/or CD8 + donor specific alloreactive T cells. The capacity to mount an anamnestic rejection could persist several weeks or months after completion of the first graft rejection, suggesting that memory T cells had been produced following the first transplant. However the mechanisms of memory induction and the phenotypic and functional differences between memory and effector T cells remain controversial. The allograft response entails the clonal expansion of donor MHC class II and MHC class I specific CD4 + and CD8 + T cells, associated with several phenotypic changes, including increased surface expression of CD2 and CD58 (LFA-3), increased affinity of the integrin CD11a/CD18 (LFA-1), de novo expression of the integrin α4β1 (CD29/49d, VLA-4), changes in expression of CD62L and CD44 and decrease of the CD45RA isoform with a compensatory increase of the shorter CD45RO isoform.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Etablissement Français des Greffes. Annual report from the Conseil Medical et Scientifique, 1996.
Traeger J, Touraine JL, Malik MC, Revillard JP, Laville M. Antilymphocyte globulin and thoracic duct drainage in renal transplantation. Kidney Int. 1983; 23(Suppl. 14); S74–S81.
Touraine JL, Traeger J, Bétuel H et al Antilymphocyte globulin in renal transplantation. Transplant Clin. Immunol. 1983; 15: 41–47.
Revillard JP, Laville M, Vincent C. Serum C-reactive protein assay in renal transplantation. In: Allen R, Bienvenu J, Laurent P, Suskind R (eds.), Marker Proteins in Inflammation. Walter de Gruyter, Berlin, 1982, pp. 509–510.
Constant S, Zain M, Pasqualini T, Ranney P, Bottomly K. Are primed CD4 + T lymphocytes different from unprimed cells? Eur. J. Immunol. 1994; 24: 1073–1079.
Luqman M, Bottomly K. Activation requirements for CD4 + T cells differing in CD45R expression. J. Immunol. 1992; 149: 2300–2306.
Johnson JG, Jenkins MK. Monocytes provide a novel costimulatory signal to T cells that is not mediated by the CD28/B7 interaction. J. Immunol. 1994; 152: 429–437.
Van de Velde I, Lorré K, Bakkus M, Thielemans K, Ceuppens L, de Boer M. CD45RO + memory T cells but not CD45RA + naive T cells can be efficiently activated by remote co-stimulation with B7. Int. Immunol. 1993; 5: 1483–1487.
Anasetti C, Tan P, Hansen JA, Martin PJ. Induction of specific nonresponsiveness in unprimed human T cells by anti-CD3 antibody and alloantigen. J. Exp. Med. 1990; 172: 1691–1700.
Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw J, Ledbetter JA, Linsley PS. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its ligand B7/BB1. J. Exp. Med. 1993; 177: 165–173.
Vincent C, Fournel S, Wijdenes J, Revillard JP. Specific hyporesponsiveness of alloreactive peripheral T cells induced by CD4 antibodies. Eur. J. Immunol. 1995; 25: 816–822.
Fournel S, Vincent C, Assossou O et al. CD4 mAbs prevent progression of alloactivated CD4 + T cells into the S phase of the cell cycle without interfering with early activation signals. Transplantation 1996; 62: 1136–1143.
Robinet E, Fournel S, Fatmi A, Revillard JP. IL-2-resistant hyporesponsiveness induced by CD4 mAbs in OKT3-activated human T cells is reversed by CD45RA triggering. Cell Immunol. 1996; 167: 1–7.
Gupta M, Satyaraj E, Durkik JM, Rath S, Bal V. Differential regulation of T cell activation for primary versus secondary proliferative responses. J. Immunol. 1997; 158: 4113–4121.
Lynch DH, Ramsdell F, Alderson MR. Fas and Fas-L in the homeostatic regulation of immune responses. Immunol. Today 1995; 16: 569–574.
Trauth BC, Klas C, Peters AMJ, Matzku S, Möller P, Falk W, Debatin KM, Krammer PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301–305.
Itoh N., Yonehara S, Ishii A et al. The polypeptide encoded by cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233–243.
Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 1994; 76: 959–962.
Armitage RJ. Tumor necrosis factor receptor superfamily members and their ligands. Curr. Opin. Immunol. 1994; 6: 407–413.
Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169–1178.
Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J. Exp. Med. 1994; 179: 873.
Suda T, Okazaki T, Naito Y et al. Expression of the Fas ligand in cells of T cell lineage. J. Immunol. 1995; 154: 3806–3813.
Kayagaki N, Kawasaki A, Ebata T et al. Metalloproteinase-mediated reiease of human Fas ligand. J. Exp. Med. 1995; 182: 1777–1783.
Mariani SM, Matiba B, Baümler C, Krammer PH. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur. J. Immunol. 1995; 25: 2303–2304.
Watanabe-Fukanaga RC, Brannan I, Coneland NG et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314–317.
Ramsdell, F, Seaman MS, Miller RE, Tough TW, Alderson MR, Lynch DH. gld/gld mice are unable to express a functional ligand for Fas. Eur. J. Immunol. 1994; 4: 928–933.
Takahashi T, Tanaka M, Brannan CI et al. Generalized lymphoproliferation disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969–976.
Rieux-Laucat F, Le Deist F, Hivroz C et ai. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268: 1347–1349.
Fisher GH, Rosenberg FJ, Straus SE et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81: 935–946.
MacDonald HR, Baschieri S, Lees RK. Clonal expansion precedes anergy and death of Vβ8 + peripheral T cells responding to staphylococcal enterotoxin B in vivo. Eur. J. Immunol. 1991; 21: 1963–1966.
Lenardo MJ. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 1991; 353: 858–861.
Klas C, Debatin KM, Jonker RR, Krammer PH. Activation interferes with the Apo-1 pathway in mature human T cells. Int. Immunol. 1993; 5: 625–630.
Fournel S, Genestier L, Robinet E, Flacher M, Revillard JP. Human T cells require IL-2 but not G1/S transition to acquire susceptibility to Fas-mediated apoptosis. J. Immunol. 1996; 157: 4309–4315.
Wang R, Rogers AM, Rush BJ, Russel JH. Induction of sensitivity to activation-induced death in primary CD4 + cell: a role for interleukin-2 in the negative regulation of response by mature CD4 + cells. Eur. J. Immunol. 1996; 26: 2263–2270.
Kneitz B, Herrmann T, Yonera S, Schimpl A. Normal clonal expansion but impaired Fasmediated cell death and anergy induction in interleukin-2-deficient mice. Eur. J. Immunol. 1995; 25: 2572–2577.
Kündig, TM, Schorle H, Bachmann MF et al. Immune responses in interleukin-2-deficient mice. Science 1993; 262: 1059–1061.
Willerford DM, Chen J, Ferry JA et al. Interleukin-2 receptor a chain regulates the size and content of the peripheral lymphoid. Immunity 1995; 3: 521–530.
Suzuki H, Kündig TM, Furlonger C et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor β. Nature 1995; 268: 1472–1476.
Anel A, Buferne M, Boyer C, Schmitt-Verhulst A-M, Golstein P. T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A. Eur. J. Immunol. 1994; 24: 2469–2476.
Sambhara SR, Miller RG. Programmed cell death of T cells signaled by the T cell receptor and the α3 domain of class I CMH. Science 1991; 252: 1424–1427.
Genestier L, Paillot R, Bonnefoy-Berard N, Waldmann H, Revillard JP. T cell sensitivity to HLA class I-mediated apoptosis is dependent on IL-2 and IL-4. Eur. J. Immunol. 1997; 27: 495–499.
Genestier L, Paillot R, Bonnefoy-Berard N et al. Fas independent apoptosis of activated T cells induced by antibodies to the HLA class I α1 domain. Blood 1997; 90 (in press, Nov. issue).
Genestier L, Meffre G, Garrone P et al. Antibodies to HLA class I α1 domain trigger apoptosis of CD40-activated human B lymphocytes. Blood 1997; 90: 726–735.
Mollereau B, Deckert M, Déas O et al. CD2-induced apoptosis in activated human peripheral T cells: A Fas-independent pathway that requires early protein tyrosine phosphorylation. J. Immunol. 1996; 151: 3184–3190.
Gonzalez-Garcia A, Borlando L, Leonardo E, Mérida I, Martinez A, Carrera AC. Lck is necessary and sufficient for Fas-ligand expression and apoptotic cell death in mature cycling T cells. J. Immunol. 1997; 158: 4104–4112.
Gribben JG, Freeman GJ, Boussiotis VA et al. CTLA-4 mediates antigen-specific apoptosis of human T cells. Proc. Natl. Acad. Sci. USA 1995; 92: 811–815.
Lee SY, Park CG, Choi Y. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with Tumor Necrosis Factor receptor-associated factors. J. Exp. Med. 1996; 183: 669–674.
Klaus SJ, Sidorenko SP, Clark EA. CD45 ligation induces programmed cell death in T and B lymphocytes. J. Immunol. 1996; 156: 2743–2753.
Brown TJ, Shuford WW, Wang W-C et al. Characterization of a CD43/leukosialin-mediated pathway for inducing apoptosis in human T-lymphoblastoid cells. J. Biol. Chem. 1996; 271: 27686–27695.
Hess S, Engelmann H. A novel function of CD40: induction of cell death in transformed cells. J. Exp. Med. 1996; 183: 159–167.
Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc. Natl. Acad. Sci. USA 1991; 88: 2441–2445.
Friesen C, Herr I, Krammer P, Debatin K-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med. 1996; 2: 574–577.
Müller M, Strand S, Hug H et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 1997; 99: 403–413.
Rights and permissions
Copyright information
© 1997 Kluwer Academic Publishers
About this chapter
Cite this chapter
Fournel, S. et al. (1997). Immunological rationale for induction therapy in patients with donor-specific memory T cells. In: Retransplantation. Transplantation and Clinical Immunology, vol 29. Springer, Dordrecht. https://doi.org/10.1007/978-0-585-38142-8_16
Download citation
DOI: https://doi.org/10.1007/978-0-585-38142-8_16
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-4937-2
Online ISBN: 978-0-585-38142-8
eBook Packages: Springer Book Archive